Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma
Robert S. McNeill(University of North Carolina at Chapel Hill), C. Ryan Miller(University of North Carolina at Chapel Hill), Kasey Skinner(University of North Carolina at Chapel Hill), Carey K. Anders(Duke University), Jann N. Sarkaria(Mayo Clinic in Arizona), Ryan Bash(University of North Carolina at Chapel Hill), Harshil Dhruv(Arysta LifeScience (France)), Timothy J. Stuhlmiller(University of North Carolina at Chapel Hill), Gary L. Johnson(University of Colorado Hospital), Demitra A. Canoutas(University of North Carolina at Chapel Hill), Laura E. Herring(University of North Carolina at Chapel Hill), Erik P. Sulman(NYU Langone Health), Michael E. Berens(Translational Genomics Research Institute), Juanita C. Limas(University of North Carolina at Chapel Hill), Steven P. Angus(University of North Carolina at Chapel Hill), Xin Chen(Qingdao University), Ralf S. Schmid(University of North Carolina at Chapel Hill), David Irvin(University of North Carolina at Chapel Hill), Lee M. Graves(University of North Carolina at Chapel Hill), Michael Hadler(University of North Carolina at Chapel Hill), Jeremy M. Simon(Harvard University), Marni B. Siegel(University of North Carolina at Chapel Hill), Amanda E.D. Van Swearingen(Duke Cancer Institute)
Cited by 63
Related Papers
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
An integrated encyclopedia of DNA elements in the human genome
|The Journal of the American Medical Association (JAMA) Network (American Medical Association)|2012|2.8k
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
|Nature|2017|2k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Brain metastases
|Nature Reviews Disease Primers|2019|1.1k